Edward Wu
Psychiatry · Kaneohe, HINPI 1265598718
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 468 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,428 and has fallen 57.8% since, to $1,448 in 2024. Among psychiatry clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 468 payments — averaging $27.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Sunovion Pharmaceuticals Inc.$2K
- AbbVie$2K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$988
- Takeda Pharmaceuticals U.S.A., Inc.$753
- plus $3K from 9 others
What the payments were for
- Food & beverage$12,87999%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 76 | $2,424 |
| Sunovion Pharmaceuticals Inc. | 72 | $2,328 |
| AbbVie(2 entities) | 89 | $2,316 |
| Alkermes, Inc. | 44 | $1,398 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $988 |
| Takeda Pharmaceuticals U.S.A., Inc. | 56 | $753 |
| Lundbeck LLC | 41 | $686 |
| Johnson & Johnson | 21 | $606 |
| Teva Pharmaceuticals USA, Inc. | 4 | $398 |
| Eisai Inc. | 9 | $350 |
| Neurocrine Biosciences, Inc. | 9 | $322 |
| Axsome Therapeutics, Inc. | 3 | $244 |
| Indivior Inc. | 4 | $99 |
| Merck | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,918
- VRAYLAR$843
- ABILIFY MAINTENA$693
- LATUDA$588
- REXULTI$485
- ARISTADA INITIO$480
- CAPLYTA$457
- LYBALVI$440
- AUSTEDO$251
- ABILIFY ASIMTUFII$247
- Dayvigo$239
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- SPRAVATO$125
- INGREZZA$123
- Auvelity$122
- UZEDY$119
How this compares
$12,971 in reported general payments places this provider in the 95th percentile of 183 psychiatry providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 13 | $16,749 |
| XanaxAlprazolam | 11 | $4,302 |
| Vilazodone Hcl | 12 | $1,443 |
| Quetiapine Fumarate | 27 | $1,148 |
| Bupropion XlBupropion Hcl | 48 | $933 |
| Alprazolam | 77 | $856 |
| Aripiprazole | 26 | $608 |
| Zolpidem Tartrate | 62 | $488 |
| Buspirone Hcl | 22 | $342 |
| Sertraline Hcl | 74 | $337 |
| Diazepam | 35 | $246 |
| Olanzapine | 12 | $229 |
| Trazodone Hcl | 48 | $164 |
| Fluoxetine Hcl | 14 | $156 |
| Escitalopram Oxalate | 25 | $150 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Kaneohe
- Clayton ChanKaneohe$2K
- Edmund ValerioKaneohe$1K
- Denis Mee-LeeHonolulu$526K
- David SteinHonolulu$186K
- Michael ZafraniAiea$29K
- Jon CooneyAiea$21K
- Harry ChingonAiea$15K
- Peter YamamotoWaianae$13K
- Gregory YuenHonolulu$6K
- Raymond DavidsonHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.